Altre lingue SpringWorks Therapeutics, Inc.

Azioni

SWTX

US85205L1070

Tempo reale stimato Cboe BZX Altri mercati azionari 17:50:38 01/05/2024			Variaz. 5gg	Var. 1 gen.
46,32 ^USD	-0,78%		+4,67%	+24,40%

12/03	Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM
07/03	SPRINGWORKS THERAPEUTICS, INC. : JPMorgan Chase mantiene la raccomandazione Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024	18/04
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment	04/03
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	04/03
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	04/03
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	29/02
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	29/02
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows	27/02
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
SpringWorks Therapeutics: Q4 Earnings Snapshot	27/02
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M	27/02
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	27/02
SpringWorks Therapeutics to Present at Upcoming Investor Conferences	22/02
Springworks Therapeutics Insider Sold Shares Worth $1,160,362, According to a Recent SEC Filing	06/02
SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer	02/02
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31/01
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31/01
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference	08/01
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	21/12
SpringWorks Therapeutics Closes $316.3 Million Common Stock Public Offering	08/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue SpringWorks Therapeutics, Inc.

Azioni

SWTX

US85205L1070

Altre lingue

Filtri